Shares of Vivus up on anticipation of phase 3 data on new ED drug (VVUS)

Shares of Vivus(VVUS) are up 4% in a down market today, as the company said they will share phase 3 data about their new erectile dysfunction drug Avanafil.


From the release:

MOUNTAIN VIEW, Calif., May 28, /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq:VVUS - News) today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 (PDE5) inhibitor therapy being investigated for the treatment of erectile dysfunction (ED), will be presented next Tuesday at the American Urological Association (AUA) 2010 Annual Meeting inSan Francisco, California.

The key thing being that it is ingested orally, unlike their previous efforts to combat ED.  Ouch.